Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rupal Satish Bhatt, M.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA196996 (BHATT, RUPAL S) Aug 1, 2015 - Jul 31, 2020
    NIH/NCI
    Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
    Role: Principal Investigator
  2. K08CA138900 (BHATT, RUPAL S) Aug 11, 2010 - Jul 31, 2015
    NIH/NCI
    Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Melms JC, Thummalapalli R, Shaw K, Ye H, Tsai L, Bhatt RS, Izar B. Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic. J Immunother Cancer. 2018 Sep 12; 6(1):89. PMID: 30208947.
    Citations:    Fields:    
  2. Scelo G, Muller DC, Riboli E, Johansson M, Cross AJ, Vineis P, Tsilidis KK, Brennan P, Boeing H, Peeters PHM, Vermeulen RCH, Overvad K, Bueno-de-Mesquita HB, Severi G, Perduca V, Kvaskoff M, Trichopoulou A, La Vecchia C, Karakatsani A, Palli D, Sieri S, Panico S, Weiderpass E, Sandanger TM, Nøst TH, Agudo A, Quirós JR, Rodríguez-Barranco M, Chirlaque MD, Key TJ, Khanna P, Bonventre JV, Sabbisetti VS, Bhatt RS. KIM-1 as a Blood-Based Marker for Early Detection of Kidney Cancer: A Prospective Nested Case-Control Study. Clin Cancer Res. 2018 Nov 15; 24(22):5594-5601. PMID: 30037816.
    Citations:    Fields:    
  3. Gao X, Jegede O, Gray C, Catalano PJ, Novak J, Kwiatkowski DJ, McKay RR, George DJ, Choueiri TK, McDermott DF, Signoretti S, Bhatt RS. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):341-348. PMID: 29754934.
    Citations:    Fields:    
  4. Hu J, Schokrpur S, Archang M, Hermann K, Sharrow AC, Khanna P, Novak J, Signoretti S, Bhatt RS, Knudsen BS, Xu H, Wu L. A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. Mol Ther Methods Clin Dev. 2018 Jun 15; 9:203-210. PMID: 29766028.
    Citations:    
  5. Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S. Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 2017 Nov 28; 8(61):103428-103436. PMID: 29262573.
    Citations:    Fields:    
  6. Sitohy B, Chang S, Sciuto TE, Masse E, Shen M, Kang PM, Jaminet SC, Benjamin LE, Bhatt RS, Dvorak AM, Nagy JA, Dvorak HF. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels. Am J Pathol. 2017 Oct; 187(10):2337-2347. PMID: 28736316.
    Citations:    Fields:    Translation:AnimalsCells
  7. Boos J, Revah G, Brook OR, Rangaswamy B, Bhatt RS, Brook A, Raptopoulos V. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma. AJR Am J Roentgenol. 2017 Aug; 209(2):W85-W92. PMID: 28570097.
    Citations:    Fields:    Translation:Humans
  8. Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB. The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clin Cancer Res. 2017 Jul 15; 23(14):3557-3565. PMID: 28031424.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  9. Pal SK, Drabkin HA, Reeves JA, Hainsworth JD, Hazel SE, Paggiarino DA, Wojciak J, Woodnutt G, Bhatt RS. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. Cancer. 2017 Feb 15; 123(4):576-582. PMID: 27727447.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  10. Wang X, Solban N, Khanna P, Callea M, Song J, Alsop DC, Pearsall RS, Atkins MB, Mier JW, Signoretti S, Alimzhanov M, Kumar R, Bhasin MK, Bhatt RS. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget. 2016 Jul 05; 7(27):41857-41869. PMID: 27248821.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  11. Mahoney KM, Jacobus S, Bhatt RS, Song J, Carvo I, Cheng SC, Simpson M, Fay AP, Puzanov I, Michaelson MD, Atkins MB, McDermott DF, Signoretti S, Choueiri TK. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6. PMID: 27036973.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  12. McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, Ghoroghchian PP, Bhatt RS, Kaffenberger SD, Simantov R, Choueiri TK, Heng DY. Statins and survival outcomes in patients with metastatic renal cell carcinoma. Eur J Cancer. 2016 Jan; 52:155-62. PMID: 26687834.
    Citations: 4     Fields:    Translation:Humans
  13. Varma G, Wang X, Vinogradov E, Bhatt RS, Sukhatme VP, Seth P, Lenkinski RE, Alsop DC, Grant AK. Selective spectroscopic imaging of hyperpolarized pyruvate and its metabolites using a single-echo variable phase advance method in balanced SSFP. Magn Reson Med. 2016 10; 76(4):1102-15. PMID: 26507361.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  14. Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015 Oct; 3(10):1158-64. PMID: 26014095; PMCID: PMC4596765.
    Citations: 52     Fields:    Translation:HumansCells
  15. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2471-9. PMID: 25724518; PMCID: PMC4566854.
    Citations: 19     Fields:    Translation:Humans
  16. Plymate SR, Bhatt RS, Balk SP. Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2. Cancer Cell. 2015 Feb 09; 27(2):158-9. PMID: 25670076.
    Citations: 4     Fields:    Translation:HumansAnimals
  17. Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res. 2015 Apr 15; 21(8):1925-1934. PMID: 25589614; PMCID: PMC4419371.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  18. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8. PMID: 25424850; PMCID: PMC4315731.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  19. Bhatt RS, Atkins MB. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin Cancer Res. 2014 Jun 01; 20(11):2838-45. PMID: 24714770; PMCID: PMC4112731.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  20. Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS. The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol. 2014 Apr; 7(2):188-95. PMID: 24704536; PMCID: PMC4101387.
    Citations: 7     
  21. Beddy P, Genega EM, Ngo L, Hindman N, Wei J, Bullock A, Bhatt RS, Atkins MB, Pedrosa I. Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma. Clin Genitourin Cancer. 2014 Feb; 12(1):55-62. PMID: 24145001; PMCID: PMC4364293.
    Citations: 8     Fields:    Translation:Humans
  22. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 01; 118(19):4777-84. PMID: 22282219; PMCID: PMC3791849.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  23. Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med. 2011 Dec 21; 9:220. PMID: 22188900; PMCID: PMC3258225.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  24. Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011 Jun 28; 105(1):112-7. PMID: 21673679; PMCID: PMC3137404.
    Citations: 7     Fields:    Translation:HumansCells
  25. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011 Apr 29; 6(4):e19144. PMID: 21559452; PMCID: PMC3084751.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  26. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther. 2010 Oct; 9(10):2793-802. PMID: 20699227; PMCID: PMC2956167.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  27. Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 2010 Apr 01; 116(7):1751-6. PMID: 20120033; PMCID: PMC2847062.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  28. Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009 Feb-Mar; 32(2):181-5. PMID: 19238017.
    Citations: 12     Fields:    Translation:Humans
  29. David J. Panka, Ph.D., Manoj Kumar, Ph.D., Rupal Bhatt, M.D., Ph.D., Rachel Schor-Bardach, M.D., Liang Zhang, M.D., S. Nahum Goldberg, M.D., Towia Libermann, Ph.D., Michael B. Atkins, M.D., and James W. Mier, M.D. Mechanisms of Acquired Resistance to VEGF Receptor Antagonists. Cancer, in Press. 2008.
  30. Bhatt RS, Bubley GJ. The challenge of herbal therapies for prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7581-2. PMID: 19047081.
    Citations: 2     Fields:    Translation:HumansAnimals
  31. Rupal S. Bhatt, Anat Norden-Zfoni, Anne O’Neill, Amado J. Zurita, Hua Kang Wu, Daniela Prox, Michael B. Atkins, and John V. Heymach. Circulating Endothelial Cells are a Potential Biomarker for Patients with and without von Hippel Lindau Syndrome . American Society of Clinical Oncology. 2008.
  32. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ. Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008 Aug; 102(3):358-63. PMID: 18394010; PMCID: PMC4112353.
    Citations: 8     Fields:    Translation:HumansCells
  33. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, J. Bubley G. HIF2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. British Journal of Urology. 2008; 102(3):358-363.
  34. Rupal S. Bhatt, Liang Zhang, Rachel Schor-Bardach, Towia Libermann, Michael B. Atkins, S. Nahum Goldberg, Manoj Bhasin, James W. Mier. . Resistance to Antiangiogenic Therapy is Accompanied by a Reversible Decrease in Interferon Gamma Signaling . American Association of Cancer Research. 2008.
  35. Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res. 2007 Apr 01; 13(7):2115-20. PMID: 17404094.
    Citations: 17     Fields:    Translation:HumansCells
  36. Bhatt RS, Seth P, Sukhatme VP. Biomarkers for monitoring antiangiogenic therapy. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):777s-780s. PMID: 17255309.
    Citations: 8     Fields:    Translation:Humans
  37. Gallagher D*, Bhatt R*, Parikh S, Patel P, Seery V, McDermott D, Atkins M, Sukhatme V, *co-first authors. Angiopoietin 2 is a potential mediator of high-dose interleukin-2 induced vascular leak. Clinical Cancer Research. 2007; 13(7).
  38. Bhatt R, Seth P, Sukhatme V. Biomarkers for monitoring antiangiogenic therapy.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):777s-780s. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):777s-780s. 2007; 13:777-780s.
  39. L.Lomo, P.Seth, T. Whitman, R. Bhatt, V. Sukhatme, E. Cibas. Circulating Tumor Cells and Endothelial Cells Can Be Easily Quantitated in Renal Cell Carcinoma Patients Using a Semi-Automated System. American Society of Cytopathology. 2006.
  40. Bhatt R, Gallagher D, Parikh S, Patel P, Seery V, McDermott D, Aktins M, Sukhatme V. Angiopoeitin 2 is a potential mediator of high-dose interleukin 2 induced vascular leak (Oral presentation). International Society of Biologic Therapy. 2006.
  41. D. F. McDermott, D. C. Cho, J. R. Merchan, R. S. Bhatt, V. Seery, J. L. Mosher, M. B. Farquhar, J. W. Mier, M. B. Atkins, V. P. Sukhatme. A phase II pilot trial of low dose, continuous infusion, or "metronomic", paclitaxel and oral celecoxib in patients with metastatic melanoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24(18S):8010.
  42. Bhatt RS, Tomoda T, Fang Y, Hatten ME. Discoidin domain receptor 1 functions in axon extension of cerebellar granule neurons. Genes Dev. 2000 Sep 01; 14(17):2216-28. PMID: 10970885; PMCID: PMC316891.
    Citations: 19     Fields:    Translation:AnimalsCells
  43. Bhatt R, Rickett A. Salmonella colitis: a mimic of Hirschsprung disease. Pediatr Radiol. 2000 Jun; 30(6):431-2. PMID: 10876834.
    Citations:    Fields:    Translation:Humans
  44. Bhatt R. DDR: A member of a novel class of RTKs, is involved in cerebellar granule cell differentiation . 2000.
  45. Tomoda T, Bhatt RS, Kuroyanagi H, Shirasawa T, Hatten ME. A mouse serine/threonine kinase homologous to C. elegans UNC51 functions in parallel fiber formation of cerebellar granule neurons. Neuron. 1999 Dec; 24(4):833-46. PMID: 10624947.
    Citations: 44     Fields:    Translation:AnimalsCells
  46. Abel T, Bhatt R, Maniatis T. A Drosophila CREB/ATF transcriptional activator binds to both fat body- and liver-specific regulatory elements. Genes Dev. 1992 Mar; 6(3):466-80. PMID: 1532159.
    Citations: 44     Fields:    Translation:AnimalsCells
  47. Bhatt R. Tissue-Specific Gene expression of the Alcohol Dehydrogenase Gene in Drosophila melanogaster (Summa cum laude) . 1992.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bhatt's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (218)
Explore
_
Co-Authors (44)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.